Monday, 26. March 2018

IDT Biologika receives three Life Science Leader’s

IDT Biologika, a globally integrated contract manufacturer of vaccines and biopharmaceuticals, honored with three 2018 CMO Leadership Awards for Compatibility, Reliability and Service. Sponsored by Life Science Leader magazine, the annual awards recognize the top contract manufacturing organizations (CMOs) serving the pharmaceutical and biopharmaceutical industries.

IDT Biologika Chief Executive Officer Andreas Kastenbauer accepted the 2018 CMO Leadership Awards on behalf of the company. “Our most important assets are our employees, whose expertise and collaborative nature complement our innovative technologies, resulting in high quality customer service and satisfaction,” said Mr. Kastenbauer. “This commitment to excellence has been recognized by the industry as highlighted by honors within these CMO Leadership Award categories. We are a true partner, offering our customers seamless end-to-end solutions to meet all of their vaccines and biologics needs. Together, we can combat diseases and epidemics worldwide.”


Winners were evaluated based on real-world experiential data and feedback from decision makers who work with contract manufacturing suppliers. IDT was judged by its customers as a top performer among more than 110 CMOs. The company achieved this high honor in three of six categories across 23 performance metrics considered important to the selection of a CMO and based on customers’ direct experience working with IDT on an outsourced project within the last 18 months. Life Science Leader teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers.

The award adds to IDT’s distinguished reputation in the contract services business and celebrates the company’s ongoing commitment to manufacturing excellence. Today, IDT offers a wide range of services during all phases of vaccine and biopharmaceutical development – from early research and process development through clinical and mass commercial manufacturing.

News Overview

CEPI Awards Contract Worth Up To USD$36 million to Consortium led by IDT to Develop MERS Vaccine more info

25th anniversary of the privatization of IDT Biologika more info

IDT Biologika acquires Dr. Felgenträger, located in the BioPharmaPark Dessau more info

A second managing director for IDT Biologika more info

Official transfer of ownership more info

Plans to Build Out New, State-of-the-Art Vaccine Manufacturing Hub in Ontario more info

IDT Biologika to purchase PMSG solely from European sources more info

30 new laboratories for the vaccines of the future more info

CMO Leadership Award 2017 more info

Company concurrently launches Ecoporc SHIGA, the first fully licensed swine vaccine for the Canadian market, during the Banff Pork Seminar more info